---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/40170863.md"
description: "$Eli Lilly(LLY.US) The most direct recent impact comes from healthcare insurance and market access:* American healthcare giants (e.g., CVS) are not including some weight-loss drugs in the Medicare reimbursement system.* This directly affects Eli Lilly's core growth engine — weight-loss/metabolic drugs.But don't panic, the buying point hasn't arrived yet."
datetime: "2026-04-24T10:39:04.000Z"
locales:
  - [en](https://longbridge.com/en/topics/40170863.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/40170863.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/40170863.md)
author: "[zhou_eepOzK](https://longbridge.com/en/profiles/19749694.md)"
---

# $Eli Lilly(LLY.US) The most direct recent impact c…


### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [CVS.US](https://longbridge.com/en/quote/CVS.US.md)

## Comments (2)

- **發條陳 · 2026-04-24T10:47:55.000Z**: Does that mean it will fall further?
  - **zhou_eepOzK** (2026-04-25T01:08:53.000Z): This stock is likely to be quite volatile recently, with quite a few negative factors: Eli Lilly's newly launched oral weight-loss drug Foundayo showed moderate prescription data in its second week on